Why Sinovac Is Poised to Keep Pulling Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sinovac Biotech (NASDAQ:SVA) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Sinovac and see what CAPS investors are saying about the stock right now.

Sinovac facts

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 33% of the 66 All-Star members who have rated Sinovac believe the stock will underperform the S&P 500 going forward.

Earlier today, one of those Fools, zzlangerhans, succinctly summed up the bear case for our community:

Sinovac is now back in unsustainable territory due to the double whammy of a new bird flu epidemic and positive results for the EV71 vaccine for hand-foot-mouth disease. As always, the flu scare will resolve itself without any contribution from Sinovac or any long-term impact on their revenues. And EV71 is no doubt benefiting from public confusion over hand-foot-mouth disease, a benign illness of children that sounds a lot like hoof-and-mouth disease, an economically disastrous disease of cattle. Not every childhood viral illness requires a vaccine. I suspect that even though a few hundred children die of hand-foot-mouth out the million who contract it every year in China, the Chinese government won't see it as a public health issue pressing enough to require a new vaccination program. Eventually, Sinovac will have to live or die based on their hepatitis vaccine programs which of late have looked somewhat stagnant.

{sfr%}

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.